

Trying 3106016892...Open

Welcome to STN International! Enter x:x
 LOGINID:ssspta1653hxp
 PASSWORD:
 TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 Sep 29 The Philippines Inventory of Chemicals and Chemical
 Substances (PICCS) has been added to CHEMLIST
 NEWS 3 Oct 27 New Extraction Code PAX now available in Derwent
 Files
 NEWS 4 Oct 27 SET ABBREVIATIONS and SET PLURALS extended in
 Derwent World Patents Index files
 NEWS 5 Oct 27 Patent Assignee Code Dictionary now available
 in Derwent Patent Files
 NEWS 6 Oct 27 Plasdoc Key Serials Dictionary and Echoing added to
 Derwent Subscriber Files WPIDS and WPIX
 NEWS 7 Nov 29 Derwent announces further increase in updates for DWPI
 NEWS 8 Dec 5 French Multi-Disciplinary Database PASCAL Now on STN
 NEWS 9 Dec 5 Trademarks on STN - New DEMAS and EUMAS Files
 NEWS 10 Dec 15 2001 STN Pricing
 NEWS 11 Dec 17 Merged CEABA-VTB for chemical engineering and
 biotechnology
 NEWS 12 Dec 17 Corrosion Abstracts on STN
 NEWS 13 Dec 17 SYNTHLINE from Prouis Science now available on STN
 NEWS 14 Dec 17 The CA Lexicon available in the CAPLUS and CA files
 NEWS 15 Jan 05 AIDSLINE is being removed from STN

 NEWS EXPRESS FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER!
 (WINDOWS) NOW AVAILABLE
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:19:29 ON 12 JAN 2001

=> file biosis, medline, fsta, jicst, uspat, wpids, hcaplus, dgene, frosti,
 cen, ceaba, biotechds, biotechabs, scisearch,

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

0.45

SESSION
0.45

FILE 'BIOSIS' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 15:21:09 ON 12 JAN 2001

FILE 'FSTA' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'USPATFULL' ENTERED AT 15:21:09 ON 12 JAN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'HCAPLUS' ENTERED AT 15:21:09 ON 12 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'FROSTI' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'CEN' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (c) 2001 DECHEMA eV

FILE 'BIOTECHDS' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'SCISEARCH' ENTERED AT 15:21:09 ON 12 JAN 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

=> s nuclease

L1 83691 NUCLEASE

=> s DNA ligase IV

L2 216 DNA LIGASE IV

=> s l1 and l2

L3 2 L1 AND L2

=> s l1 and method

L4 18092 L1 AND METHOD

=> s 13 and 14

L5 2 L3 AND

=> d 15 ti abs ibib tot

L5 ANSWER 1 OF 2 USPATFULL

TI Inhibition of cell growth by an anti-proliferative factor

AB The present invention involves the identification of a factor or factors

that are anti-proliferative and can be used in the treatment of cancers and other hyperproliferative disease states. The factor or factors are induced from cells follow contact of the cells with viral or plasmid expression vectors. One factor is between about 3 kDa and 300 kDa in size, while another is less than about 3 kDa in size. Both are heat stable and is resistant to both protease and **nuclease** treatment. Methods for purification and use of the factor also are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:138501 USPATFULL

TITLE: Inhibition of cell growth by an anti-proliferative factor

INVENTOR(S): Wilson, Deborah R., Houston, TX, United States
Lapadat-Tapolsky, Mary, The Woodlands, TX, United States

Timmons, Therese M., Houston, TX, United States

Lee, Julia A., Houston, TX, United States

Almond, Brian D., Houston, TX, United States

Roth, Jack A., Houston, TX, United States

PATENT ASSIGNEE(S): The University of Texas System Board of Regents,
Austin, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6133416	20001017
APPLICATION INFO.:	US 1997-918712	19970822 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24343	19960823 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Eyler, Yvonne	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	2844	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 2 USPATFULL

TI Methods of assaying differential expression

AB Methods and compositions are provided for analyzing differences in the RNA profiles between a plurality of different physiological samples. In the subject methods, a set of a representational number of distinct gene

specific primers is used to generate labeled nucleic acids from each of the different physiological samples. The labeled nucleic acids are then compared to each other and differences in the RNA profiles are determined. The subject methods find use in methods of identifying differential gene expression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:155460 USPATFULL

TITLE: Methods of assaying differential expression

INVENTOR(S): Chenchik, Alex, Palo Alto, CA, United States
Jokhadze, George, Mountain View, CA, United States
Bibilashvilli, Robert, Moscow, Russian Federation
PATENT ASSIGNEE(S): Clontech Laboratories, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5994076	19991130
APPLICATION INFO.:	US 1997-859998	19970521 (8)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Fredman, Jeffrey	
LEGAL REPRESENTATIVE:	Bozicevic & Reed LLP; Field, Bret E.	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	13450	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 15:19:29 ON 12 JAN 2001)

FILE 'BIOSIS, MEDLINE, FSTA, JICST-EPLUS, USPATFULL, WPIDS, HCAPLUS, DGENE, FROSTI, CEN, CEABA-VTB, BIOTECHDS, SCISEARCH' ENTERED AT 15:21:09 ON 12 JAN 2001

L1 83691 S NUCLEASE
L2 216 S DNA LIGASE IV
L3 2 S L1 AND L2
L4 18092 S L1 AND METHOD
L5 2 S L3 AND L4

=> s l4 and (degradation of DNA ligase IV)

L6 0 L4 AND (DEGRADATION OF DNA LIGASE IV)

=> s l4 and (activity of DNA ligase IV?)

11 FILES SEARCHED...

L7 0 L4 AND (ACTIVITY OF DNA LIGASE IV?)

=> s degradation and (DNA ligase IV)

L8 6 DEGRADATION AND (DNA LIGASE IV)

=> s l8 and l4

L9 2 L8 AND L4

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 2 USPATFULL

TI Inhibition of cell growth by an anti-proliferative factor

AB The present invention involves the identification of a factor or factors

that are anti-proliferative and can be used in the treatment of cancers and other hyperproliferative disease states. The factor or factors are

induced from cells follow contact of the cells with viral or plasmid expression vectors. One factor is between about 10 kDa and 300 kDa in size, while another is less than about 3 kDa in size. Both are heat stable and is resistant to both protease and **nuclease** treatment. Methods for purification and use of the factor also are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:138501 USPATFULL
TITLE: Inhibition of cell growth by an anti-proliferative factor
INVENTOR(S): Wilson, Deborah R., Houston, TX, United States
Lapadat-Tapolsky, Mary, The Woodlands, TX, United States
Timmons, Therese M., Houston, TX, United States
Lee, Julia A., Houston, TX, United States
Almond, Brian D., Houston, TX, United States
Roth, Jack A., Houston, TX, United States
PATENT ASSIGNEE(S): The University of Texas System Board of Regents,
Austin, TX, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6133416	20001017
APPLICATION INFO.:	US 1997-918712	19970822 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24343	19960823 (60)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Eyler, Yvonne	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	2844	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 2 USPATFULL

TI Methods of assaying differential expression

AB Methods and compositions are provided for analyzing differences in the RNA profiles between a plurality of different physiological samples. In the subject methods, a set of a representational number of distinct

gene

specific primers is used to generate labeled nucleic acids from each of the different physiological samples. The labeled nucleic acids are then compared to each other and differences in the RNA profiles are determined. The subject methods find use in methods of identifying differential gene expression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:155460 USPATFULL
TITLE: Methods of assaying differential expression
INVENTOR(S): Chenchik, Alex, Palo Alto, CA, United States
Jokhadze, George, Mountain View, CA, United States
Bibilashvilli, Robert, Moscow, Russian Federation
PATENT ASSIGNEE(S): Clontech Laboratories, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5994076	19991130
APPLICATION INFO.:	US 1997-859998	19970521 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fredman, Jeffrey
LEGAL REPRESENTATIVE: Bozicevic & Reed LLP; Field, Bruce E.
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 13450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s xrcc4?

L10 240 XRCC4?

=> d his

(FILE 'HOME' ENTERED AT 15:19:29 ON 12 JAN 2001)

FILE 'BIOSIS, MEDLINE, FSTA, JICST-EPLUS, USPATFULL, WPIDS, HCAPLUS, DGENE, FROSTI, CEN, CEABA-VTB, BIOTECHDS, SCISEARCH' ENTERED AT 15:21:09 ON 12 JAN 2001

L1 83691 S NUCLEASE
L2 216 S DNA LIGASE IV
L3 2 S L1 AND L2
L4 18092 S L1 AND METHOD
L5 2 S L3 AND L4
L6 0 S L4 AND (DEGRADATION OF DNA LIGASE IV)
L7 0 S L4 AND (ACTIVITY OF DNA LIGASE IV?)
L8 6 S DEGRADATION AND (DNA LIGASE IV)
L9 2 S L8 AND L4
L10 240 S XRCC4?

=> s l10 and l2

L11 129 L10 AND L2

=> s l11 and method

L12 20 L11 AND METHOD

=> s l12 and assay

L13 2 L12 AND ASSAY

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 2 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Modulation of cellular DNA repair activity - using compounds identified
as

modulating the interaction of **XRCC4**, **DNA ligase IV** and DNA-PKcs/Ku.

AN 1998-399301 [34] WPIDS

CR 1998-379674 [33]

AB WO 9830902 A UPAB: 20001016

Assaying for a compound able to modulate the interaction or binding between **XRCC4** and any of **DNA ligase IV** and/or DNA-PKcs/Ku (DPK) comprises: (a) bringing into contact: (i) a substance including **XRCC4** (or a fragment, derivative, variant or analogue able to bind **DNA ligase IV** or DPK); (ii) a substance including **DNA ligase IV** (or a fragment, derivative, variant or analogue able to bind

XRCC4; and/or (iii) DPK (or a fragment, derivative, variant or analogue able to bind XRCC4), and a test compound under conditions where, if the test compound is not an inhibitor of interaction or binding between the substances, the substances interact or bind; and (b) determining interaction or binding between the substances.

Also claimed are: (1) assaying for a compound able to affect DNA ligase IV activity, comprising: (a) bringing into contact DNA ligase IV and a test compound; and (b) determining DNA ligase activity; (2) an assay method including: (a) bringing into contact: (i) a substance which includes DPK or a fragment, derivative, variant or analogue able to phosphorylate XRCC4; (ii) a substance which includes XRCC4 or a fragment, derivative, variant or analogue able to bind XRCC4 including a site phosphorylated by DPK; and (iii) a test compound; and (b) determining phosphorylation at the site; (3) an agent capable of: (a) modulating the interaction between XRCC4 and any of DNA ligase IV and/or DPK; (b) affecting DNA ligase IV activity; or (c) affecting DPK phosphorylation of XRCC4, obtained using a method as above; (4) a peptide fragment (A) of DNA ligase IV capable of modulating interaction between XRCC4 and any of DNA ligase IV and/or DPK; (5) a nucleic acid (I) encoding (A); (6) a peptide fragment of XRCC4 (B) capable of modulating interaction between XRCC4 and DNA ligase IV; (7) a nucleic acid (II) encoding (B); and (8) a method for screening an individual for a predisposition to a disorder in which DNA repair plays a role, comprising determining from a sample taken from the individual the presence or absence of a defect in XRCC4 and/or DNA ligase IV activity.

USE - Compounds which modulate the interaction between XRCC4, DNA ligase IV and DPK can be used to modulate cellular DNA repair activity, e.g. in the treatment of proliferative disorders, cancers and tumours, disorders involving retroviruses such as AIDS, human adult T-cell leukaemia/lymphoma, Type I diabetes and multiple sclerosis, and also in radiotherapy and chemotherapy. They can also be used in the potentiation of gene targeting and gene therapy. They can also be used for the modulation of immune system function.

Dwg.0/6

ACCESSION NUMBER: 1998-399301 [34] WPIDS
CROSS REFERENCE: 1998-379674 [33]
DOC. NO. NON-CPI: N1998-310586
DOC. NO. CPI: C1998-121060
TITLE: Modulation of cellular DNA repair activity - using compounds identified as modulating the interaction of XRCC4, DNA ligase IV and DNA-PKcs/Ku.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): CRITCHLOW, S E; JACKSON, S P
PATENT ASSIGNEE(S): (CANC-N) CANCER RES CAMPAIGN TECHNOLOGY
COUNTRY COUNT: 82
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG																		
WO 9830902	A1	19980716	(199834)*	EN	118																		
RW:	AT	BE	CH	DE	DK	EA	ES	FI	FR	GB	GH	GM	GR	IE	IT	KE	LS	LU	MC	MW	NL	OA	
	PT	SD	SE	SZ	UG	ZW																	
W:	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	CA	CH	CN	CU	CZ	DE	DK	EE	ES	FI	GB	GE	
	GH	GM	GW	HU	ID	IL	IS	JP	KE	KG	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MD	MG	
	MK	MN	MW	MX	NO	NZ	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL	TJ	TM	TR	TT	UA	UG	
	US	UZ	VN	YU	ZW																		

GB 2322193 A 19980819 (199835)
 AU 9855681 A 19980803 (199850)
 GB 2329248 A 19990317 (199913)
 GB 2329469 A 19990324 (199914)
 GB 2329248 B 19990922 (199941)
 GB 2329469 B 19990922 (199941)
 GB 2322193 B 19990929 (199942)
 EP 966683 A1 19991229 (200005) EN
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 AU 724108 B 20000914 (200051)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9830902	A1	WO 1998-GB95	19980113
GB 2322193	A	GB 1998-663	19980113
AU 9855681	A	AU 1998-55681	19980113
GB 2329248	A Derived from	GB 1998-663	19980113
		GB 1998-20952	19980925
GB 2329469	A Derived from	GB 1998-663	19980113
		GB 1998-20948	19980925
GB 2329248	B Derived from	GB 1998-663	19980113
		GB 1998-20952	19980925
GB 2329469	B Derived from	GB 1998-663	19980113
		GB 1998-20948	19980925
GB 2322193	B	GB 1998-663	19980113
EP 966683	A1	EP 1998-900589	19980113
		WO 1998-GB95	19980113
AU 724108	B	AU 1998-55681	19980113

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9855681	A Based on	WO 9830902
EP 966683	A1 Based on	WO 9830902
AU 724108	B Previous Publ. Based on	AU 9855681 WO 9830902

PRIORITY APPLN. INFO: GB 1997-13131 19970620; GB 1997-574
19970113

L13 ANSWER 2 OF 2 BIOTECHDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 TI Modulation of cellular DNA repair activity;
 recombinant protein production, monoclonal antibody, drug screening
 and nucleic acid for use in therapy and gene therapy
 AN 1998-09129 BIOTECHDS
 AB A new **assay method** for a compound (I) able to
 modulate the interaction or binding between **XRCC4** and
DNA-ligase-IV (DL4), or **XRCC4** and
DNA-PKcs/Ku (DPK), or **XRCC4**, DL4 and DPK, is claimed. Also
 claimed are (I) identified by this **method**, a peptide fragment
 (protein sequence specified) of DL4 with (I) activity, nucleic acid
 encoding the peptide, which can be used in gene therapy, and use of (I)
 in therapy of a disorder in which DNA repair plays a role, e.g. AIDS,
 cancer, human adult T-lymphocyte leukemia or lymphoma, diabetes type-I
 and multiple sclerosis. Also disclosed are: a yeast homolog of mammal
 DL4; use of antisense nucleic acid or ribozymes in therapy; production
 of a peptide or protein by recombinant expression of nucleic acid in a
 prokaryote or eukaryote host cell; monoclonal antibody production by
 hybridoma cell culture; and disease diagnosis using DNA probe or DNA

primer, and polymerase chain reaction, DNA fingerprinting and/or sequence

analyses. The products can also be used to increase efficiency of gene targeting and gene therapy. (118pp)

ACCESSION NUMBER: 1998-09129 BIOTECHDS

TITLE: Modulation of cellular DNA repair activity;
recombinant protein production, monoclonal antibody, drug
screening and nucleic acid for use in therapy and gene
therapy

AUTHOR: Jackson S P; Critchlow S E

PATENT ASSIGNEE: Cancer-Res.Campaign-Technol.

LOCATION: London, UK.

PATENT INFO: WO 9830902 16 Jul 1998

APPLICATION INFO: WO 1998-GB95 13 Jan 1998

PRIORITY INFO: GB 1997-13131 20 Jun 1997; GB 1997-574 13 Jan 1997

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 1998-399301 [34]